SI
ALNY icon

Sava Infond’s Alnylam Pharmaceuticals ALNY Stock Holding History

Sava Infond’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$266K Sell
885
-400
-31% -$121K 0.02% 173
2026
Q1 		$425K Hold
1,285
– – 0.06% 147
2025
Q4 		$511K Sell
1,285
-355
-22% -$157K 0.07% 129
2025
Q3 		$748K Sell
1,640
-540
-25% -$220K 0.11% 110
2025
Q2 		$711K Buy
2,180
+100
+5% +$27.7K 0.11% 110
2025
Q1 		$562K Buy
2,080
+350
+20% +$89.9K 0.11% 117
2024
Q4 		$407K Buy
+1,730
New +$455K 0.07% 126

Other funds holding ALNY

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
SSA
Sierra Summit Advisors Incline Village, Nevada $895M AUM 106% 1-Year Est. Return
OIAM
OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return
PSC
Portman Square Capital London, United Kingdom $2.11B AUM 19.71% 1-Year Est. Return
P
PensionDanmark Copenhagen O, Denmark $12B AUM

Sava Infond's ALNY Position: Q2 2026 in Review

Sava Infond reduced its Alnylam Pharmaceuticals (ALNY) stake by 31% in Q2 2026, selling an estimated $121K and leaving 885 shares worth $266K. The position accounts for 0.02% of the portfolio, ranked #173.

Sava Infond first reported a position in ALNY in Q4 2024 and has held it in 7 quarters since. The position peaked at $748K in Q3 2025. 108 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Sava Infond held 885 shares of Alnylam Pharmaceuticals worth $266K as of Q2 2026.
  • Sava Infond sold 400 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $121K.
  • Alnylam Pharmaceuticals made up 0.02% of Sava Infond's portfolio in Q2 2026, its #173 holding.
  • Sava Infond first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Sava Infond's Alnylam Pharmaceuticals position peaked at $748K in Q3 2025.
  • 108 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Sava Infond's 13F filing for Q2 2026, filed 16 Jul 2026.